Sustainability of C-Reactive Protein Apheresis in Acute Myocardial Infarction-Results from a Supplementary Data Analysis of the Exploratory C-Reactive Protein in Acute Myocardial Infarction-1 Study.
AMI
C-reactive protein
CMR
CRP apheresis
MRI
STEMI
hypoxia
infarct size
inflammation
inflammatory mediators
ischaemia
phagocytosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 Oct 2022
31 Oct 2022
Historique:
received:
06
10
2022
revised:
23
10
2022
accepted:
27
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
In the multicenter, non-randomized, exploratory C-reactive protein (CRP) Apheresis in Myocardial Infarction (CAMI-1) study, CRP apheresis after ST-Elevation Myocardial Infarction (STEMI) significantly decreased blood CRP concentrations in humans. Cardiac damage was assessed by Cardiac Magnetic Resonance (CMR1) 3−9 d after onset of STEMI symptoms and quantified by myocardial infarct size (IS; %), left ventricular ejection fraction (LVEF; %), circumferential strain (CS) and longitudinal strain (LS). Compared with the control group (n = 34), cardiac damage was significantly lower in the apheresis group (n = 32). These findings suggested improved wound healing due to CRP apheresis already within few days after the STEMI event. In the current supplementary data analysis of CAMI-1, we have tested by a follow-up CMR (CMR2) after an average of 88 (65−177) d whether the effect of CRP apheresis is clinically maintained. After this time period, wound healing in STEMI is considered complete. Whereas patients with low CRP production and a CRP gradient cut off of <0.6 mg/L/h in the hours after STEMI (9 of 32 patients in the CRP apheresis group) did not significantly benefit from CRP apheresis in CMR2, patients with high CRP production and a CRP gradient cut off of >0.6 mg/L/h (23 of 32 patients in the CRP apheresis group) showed significant treatment benefit. In the latter patients, CMR2 revealed a lower IS (−5.4%; p = 0.05), a better LVEF (+6.4%; p = 0.03), and an improved CS (−6.1%; p = 0.005). No significant improvement, however, was observed for LS (−2.9%; p = 0.1). These data suggest a sustained positive effect of CRP apheresis on heart physiology in STEMI patients with high CRP production well beyond the period of its application. The data demonstrate the sustainability of the CRP removal from plasma which is associated with less scar tissue.
Identifiants
pubmed: 36362673
pii: jcm11216446
doi: 10.3390/jcm11216446
pmc: PMC9655548
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Pentracor (Germany)
ID : none
Références
Front Cardiovasc Med. 2021 Mar 10;8:591714
pubmed: 33778017
BMJ Open. 2019 Feb 19;9(2):e024475
pubmed: 30782906
J Am Coll Cardiol. 2016 Apr 12;67(14):1674-83
pubmed: 27056772
J Clin Med. 2022 Jan 13;11(2):
pubmed: 35054095
J Clin Med. 2022 Mar 23;11(7):
pubmed: 35407379
Int J Cardiol. 2021 Apr 1;328:191-196
pubmed: 33309637
Pol Arch Intern Med. 2022 Feb 28;132(2):
pubmed: 34846110
Postepy Kardiol Interwencyjnej. 2021 Mar;17(1):21-32
pubmed: 33868414
JACC Cardiovasc Imaging. 2015 Jun;8(6):680-3
pubmed: 26068285
Case Rep Cardiol. 2018 Nov 6;2018:4767105
pubmed: 30533227
Arch Med Sci. 2017 Aug;13(5):1086-1093
pubmed: 28883850
Circ Res. 2016 Jun 24;119(1):91-112
pubmed: 27340270
J Cardiovasc Magn Reson. 2012 Sep 02;14:62
pubmed: 22937750
J Clin Med. 2021 Nov 24;10(23):
pubmed: 34884196
Med Klin Intensivmed Notfmed. 2022 Apr;117(3):191-199
pubmed: 35333926
Front Immunol. 2021 Feb 10;12:630430
pubmed: 33679775